Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Siwen Hu

Showing results (91-100 of 100) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 100 results.
Cell|October 16, 2020
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder CancerPatrick A Ott, Siwen Hu-Lieskovan, Bartosz Chmielowski, et al.
Nature Cancer|January 29, 2026
Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2026
Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In OncologySusan M Swetter, Douglas Johnson, Mark R Albertini, et al.
Nature Medicine|August 14, 2025
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2018
Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell PopulationsCurtis H Kugel, Stephen M Douglass, Marie R Webster, et al.
Cell Stem Cell|September 10, 2019
Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for CancerYanni Zhu, Drake J Smith, Yang Zhou, et al.
Cancer Discovery|April 21, 2026
Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1Katie M Campbell, Daniel G Chen, Zaid E Bustami, et al.
The New England Journal of Medicine|March 1, 2023
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced MelanomaSapna P Patel, Megan Othus, Yuanbin Chen, et al.
Cancer Discovery|March 8, 2018
Genetic Mechanisms of Immune Evasion in Colorectal CancerCatherine S Grasso, Marios Giannakis, Daniel K Wells, et al.
JAMA Dermatology|July 30, 2020
Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical BenefitDouglas Grossman, Nwanneka Okwundu, Edmund K Bartlett, et al.
Pageof 10

Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Cell|October 16, 2020
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder CancerPatrick A Ott, Siwen Hu-Lieskovan, Bartosz Chmielowski, et al.
Nature Cancer|January 29, 2026
Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2026
Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In OncologySusan M Swetter, Douglas Johnson, Mark R Albertini, et al.
Nature Medicine|August 14, 2025
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2018
Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell PopulationsCurtis H Kugel, Stephen M Douglass, Marie R Webster, et al.
Cell Stem Cell|September 10, 2019
Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for CancerYanni Zhu, Drake J Smith, Yang Zhou, et al.
Cancer Discovery|April 21, 2026
Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1Katie M Campbell, Daniel G Chen, Zaid E Bustami, et al.
The New England Journal of Medicine|March 1, 2023
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced MelanomaSapna P Patel, Megan Othus, Yuanbin Chen, et al.
Cancer Discovery|March 8, 2018
Genetic Mechanisms of Immune Evasion in Colorectal CancerCatherine S Grasso, Marios Giannakis, Daniel K Wells, et al.
JAMA Dermatology|July 30, 2020
Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical BenefitDouglas Grossman, Nwanneka Okwundu, Edmund K Bartlett, et al.
Pageof 10